Login to Your Account



Financings Roundup

Jazz Repaying Debt Ahead of Fibromyalgia Drug Decision

By Jennifer Boggs


Wednesday, May 12, 2010
Jazz Pharmaceuticals Inc. is raising about $58.5 million in a public offering to pay off a sizeable chunk of its outstanding debt ahead of an FDA decision on fibromyalgia drug JZP-6 (sodium oxybate), expected this fall. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription